CEL-SCI CORPORATION (CVM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 5.08M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.08M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.81M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $5.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $5.13M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $5.62M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $5.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $5.48M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $4.62M | (m) | (m) | (m) | $1.02M | (m) |
| 2024-06-30 | (m) | $5.51M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $5.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $4.87M | (m) | (m) | (m) | $2.35M | (m) |
| 2023-09-30 | (m) | $5.59M | (m) | (m) | (m) | $2.25M | (m) |
| 2023-06-30 | (m) | $5.29M | $5.14M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $5.31M | $10.05M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $4.74M | $18.02M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.66M | $22.67M | (m) | $0.00 | $2.00M | (m) |
| 2022-06-30 | (m) | $4.02M | $28.07M | (m) | $0.00 | (m) | (m) |
| 2022-03-31 | (m) | $4.47M | $34.28M | (m) | $0.00 | (m) | (m) |
| 2021-12-31 | (m) | $3.33M | $37.11M | (m) | $54.92K | (m) | (m) |
| 2021-09-30 | (m) | $3.94M | $36.06M | (m) | $54.92K | $2.01M | (m) |
| 2021-06-30 | (m) | $5.16M | $35.96M | (m) | $54.92K | $1.58M | (m) |
| 2021-03-31 | (m) | $5.82M | $6.43M | (m) | $54.92K | $1.46M | (m) |
| 2020-12-31 | (m) | $7.33M | $21.86M | (m) | $54.92K | $1.15M | (m) |
| 2020-09-30 | (m) | $4.27M | $15.51M | (m) | $54.92K | $820.05K | (m) |
| 2020-06-30 | (m) | $4.65M | $20.14M | (m) | $255.01K | $787.01K | (m) |
| 2020-03-31 | (m) | $5.27M | $14.33M | (m) | $62.29K | $849.55K | (m) |
| 2019-12-31 | (m) | $4.57M | $9.38M | (m) | $91.04K | $905.88K | (m) |
| 2019-09-30 | (m) | $3.02M | $8.44M | (m) | $62.77K | $782.36K | (m) |
| 2019-06-30 | (m) | $4.23M | $9.49M | (m) | $118.26K | $754.83K | (m) |
| 2019-03-31 | (m) | $5.47M | $5.51M | (m) | $123.24K | $761.01K | (m) |
| 2018-12-31 | (m) | $5.89M | $6.68M | (m) | $128.76K | $682.52K | (m) |
| 2018-09-30 | (m) | $9.23M | $10.31M | (m) | $118.66K | $645.24K | (m) |
| 2018-06-30 | (m) | $8.38M | $2.35M | (m) | $119.65K | $628.16K | (m) |
| 2018-03-31 | (m) | $10.86M | $3.06M | (m) | $136.78K | $630.31K | (m) |
| 2017-12-31 | (m) | $10.60M | $2.14M | (m) | $47.61K | $644.75K | (m) |
| 2017-09-30 | (m) | $10.84M | $2.37M | (m) | $218.48K | $672.52K | (m) |
| 2017-06-30 | (m) | $10.24M | $1.23M | (m) | $271.74K | $657.74K | (m) |
| 2017-03-31 | (m) | $8.41M | $1.53M | (m) | $4.25K | $678.66K | (m) |
| 2016-12-31 | (m) | $3.79M | $2.39M | (m) | $4.13K | $694.50K | (m) |
| 2016-09-30 | (m) | $4.01M | $2.92M | (m) | $394.51K | $1.01M | (m) |
| 2016-06-30 | (m) | $5.28M | $5.22M | (m) | $790.66K | $1.26M | (m) |
| 2016-03-31 | (m) | $5.09M | $6.05M | (m) | $654.83K | $1.30M | (m) |
| 2015-12-31 | (m) | $5.68M | $10.42M | (m) | $378.27K | $1.34M | (m) |
| 2015-09-30 | (m) | $6.85M | $5.73M | (m) | $87.21K | $1.40M | (m) |
| 2015-06-30 | (m) | $5.27M | $11.23M | (m) | $158.49K | $1.42M | (m) |
| 2015-03-31 | (m) | $3.68M | $2.61M | (m) | $37.43K | $1.57M | (m) |
| 2014-12-31 | (m) | $3.79M | $9.46M | (m) | $155.94K | $1.24M | (m) |
| 2014-09-30 | (m) | $3.15M | $8.51M | (m) | $81.82K | $1.45M | (m) |
| 2014-06-30 | (m) | $3.33M | $14.29M | (m) | $80.44K | $1.41M | (m) |
| 2014-03-31 | (m) | $3.32M | $10.61M | (m) | $134.95K | $1.42M | (m) |
| 2013-12-31 | (m) | $3.38M | $13.49M | (m) | $45.88K | $1.35M | (m) |
| 2013-09-30 | (m) | $3.55M | $41.61K | (m) | $74.26K | $1.02M | (m) |
| 2013-06-30 | (m) | $2.97M | $3.48M | (m) | $163.74K | $1.14M | (m) |
| 2013-03-31 | (m) | $1.88M | $6.99M | (m) | $39.56K | $1.29M | (m) |
| 2012-12-31 | (m) | $1.78M | $10.74M | (m) | $14.90K | $1.14M | (m) |
| 2012-09-30 | (m) | $1.91M | $3.94M | (m) | $158.61K | $1.38M | (m) |
| 2012-06-30 | (m) | $2.03M | $7.22M | (m) | $25.65K | $1.37M | (m) |
| 2012-03-31 | (m) | $2.03M | $5.27M | (m) | $101.46K | $1.37M | (m) |
| 2011-12-31 | (m) | $4.95M | $3.46M | (m) | $8.63K | $1.37M | (m) |
| 2011-09-30 | (m) | $7.22M | $4.26M | (m) | $457.34K | $1.57M | (m) |
| 2011-06-30 | (m) | $11.02M | $10.58M | (m) | $414.13K | $1.58M | (m) |
| 2011-03-31 | (m) | (m) | $17.74M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $20.85M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | $3.30M | $26.57M | (m) | $0.00 | $1.48M | (m) |
| 2010-06-30 | (m) | (m) | $30.48M | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | $33.57M | (m) | (m) | (m) | (m) |
| 2008-09-30 | (m) | (m) | $711.26K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |